Zolmitriptan
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Zolmitriptan: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Zolmitriptan is a triptan originally used to treat acute migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, a migraine subtype. Support is limited: there are 0 clinical trials and 19 publications, all general migraine or triptan literature rather than studies specific to this subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine disorder (acute treatment of migraine) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Structured mechanism-of-action data was not available for this report. The published literature describes zolmitriptan as a selective serotonin 5-HT1B/1D receptor agonist (a triptan). It acts both peripherally and centrally. It is thought to constrict cranial blood vessels and to inhibit trigeminovascular activation, and pre-clinical work supports this central and peripheral action.
Migraine with brainstem aura is a migraine subtype that shares the same trigeminovascular pathophysiology as the approved indication. Mechanistically the link is therefore strong, and this likely explains the very high model score.
There is an important caveat. The retrieved literature covers general migraine treatment and triptan reviews, not brainstem aura specifically. Some triptans carry cautions in brainstem or hemiplegic aura because of theoretical vascular concerns. Subtype-specific efficacy and safety data are needed before any conclusion.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine with brainstem aura.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25600718 | 2015 | Review (evidence assessment) | Headache | American Headache Society updated assessment of evidence for acute migraine drug therapies |
| 25916333 | 2015 | Meta-analysis | J Headache Pain | Compares frovatriptan with rizatriptan, zolmitriptan and almotriptan in migraine with aura. Triptans are probably not effective if taken during the aura phase. |
| 22644173 | 2012 | Subgroup analysis of a randomized crossover study | Neurol Sci | Frovatriptan vs zolmitriptan 2.5 mg in 18 patients with migraine with aura |
| 12083998 | 2002 | Review | Expert Opin Pharmacother | Zolmitriptan 2.5 and 5 mg show good efficacy in placebo-controlled trials, with onset within 45 minutes and improvement of nausea, photophobia and phonophobia |
| 10473025 | 1999 | Review | Drugs | Zolmitriptan is significantly more effective than placebo in moderate to severe migraine attacks |
| 9399012 | 1997 | Pre-clinical review | Cephalalgia | Zolmitriptan combines 5-HT1B/1D partial agonism with an ability to inhibit trigeminovascular activation centrally and peripherally |
| 23695053 | 2013 | Review of randomized studies | Neurol Sci | Triptan efficacy in hypertensive vs normotensive migraine patients |
| 12864759 | 2003 | Cohort | Headache | Transcranial Doppler blood-flow velocity during migraine attacks before and after oral zolmitriptan or sumatriptan |
| 17177580 | 2007 | Post-marketing surveillance | Clin Drug Investig | Real-life effectiveness and satisfaction with zolmitriptan 5 mg nasal spray |
| 22298171 | 2012 | Case report | Cardiol J | Zolmitriptan-induced acute myocardial infarction in a 45-year-old woman |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN11816P | ZOMIG RAPIMELT TABLET 2.5 mg | Tablet (oral) |
Safety Considerations
- Contraindications flagged in the drug-disease knowledge graph (not label text):
- Cardiovascular and cerebrovascular: coronary artery disease, myocardial infarction, myocardial ischemia, Prinzmetal angina, Wolff-Parkinson-White syndrome, hypertension, stroke, transient ischemic attack, cerebral infarction, brain ischemia, vertebrobasilar insufficiency, intracranial arteriosclerosis
- Vascular: peripheral vascular and arterial disease, intermittent claudication, Raynaud disease, ischemic bowel disease
- Other: familial or sporadic hemiplegic migraine, kidney disease, liver disease, gallbladder disease, hemoglobinopathy, pyoureter
- Drug Interactions: 82 interactions are recorded.
- Major interactions: lorcaserin, dolasetron, palonosetron, ondansetron, granisetron, dexfenfluramine, fenfluramine and sibutramine.
- Moderate interactions: morphine (including liposomal), cimetidine and obeticholic acid.
- Case-level signal: A published case report describes zolmitriptan-associated myocardial infarction.
For full warnings, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link is plausible, but evidence is at the L4 level. There are no clinical trials and no publications specific to brainstem aura. The knowledge graph also flags related contraindications, including hemiplegic migraine and cerebrovascular conditions, that raise subtype-specific safety concerns. The approved migraine indication is not in question. The open question is whether the brainstem aura subtype is a safe and useful extension.
To proceed, the following is needed:
- Subtype-specific efficacy and safety data in brainstem aura (clinical studies or case series)
- A review of cardiovascular and cerebrovascular risk for patients with brainstem or hemiplegic aura
- Package insert warnings and contraindications from HSA
- Detailed mechanism of action data from DrugBank
- A drug interaction management plan, especially for serotonergic co-medications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.